Hovering reaction driven by sound


Scientists have designed a device that can levitate materials using sound. Daniele Foresti and colleagues at ETH Zurich in Switzerland used their acoustic levitator to create this explosive mid-air reaction between a tiny water droplet and a grain of sodium. The levitator works by sending powerful ultrasound waves between an emitting surface and a reflector, which bounces them back. Where the emitted and reflected waves meet, they interfere and create stable areas that can trap small pieces of material. The positions of the waves can then be altered to move the hovering material around.

The team were able to watch chemical reactions in mid-air, mix water droplets with instant coffee granules and even levitate a toothpick. They say the levitator could have important applications in research. As the technique is completely contactless, it could be useful for processes such as DNA transfection that are vulnerable to contamination.


Related Content

Chemistry World podcast - June 2013

3 June 2013 Podcast | Monthly

news image

We discover 300 years of chemistry in Edinburgh with Eleanor Campbell, and explore the secrets of the main group elements

Chemistry World podcast - December 2013

3 December 2013 Podcast | Monthly

news image

We discover how spin chemistry guides migrating birds and explore the science of cheese

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent